TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
INCLUSION CRITERIA (Disease Characteristics):~* Diagnosis of breast cancer~  * Stage I or II disease~ * No more than 10 positive lymph nodes~ * First-time diagnosis~ * Under the age of 50 at diagnosis~* Finished active treatment within the past 2 months~* English-speaking only~* Must live within 30 miles of Magee Women's Hospital, Pittsburgh, Pennsylvania~INCLUSION CRITERIA (Patient Characteristics):~* Female patients only~* Must be able to communicate~EXCLUSION CRITERIA (Patient Characteristics):~* Other prior malignancies except skin cancer~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 49 Years
- Healthy Volunteers: f

Study Arms:
- Education Intervention (Type: EXPERIMENTAL): Participants attended 4 2-hr education sessions. The overall goal of the sessions was to provide information that would reduce participants' uncertainty about their illness and its treatment, to enhance coping in productive ways with the issues and problems confronting them, and to facilitate communication between the participants and their partners.
- Nutrition Education Intervention (Type: EXPERIMENTAL): Participants attended 4 2-hr nutrition education sessions. Each session provided information and encouragement on setting and attaining measurable goals for healthy eating and on the benefits of thinking positively about dealing adaptively with problems in life and living a healthy lifestyle.
- Control Condition (Type: NO_INTERVENTION): Participants received care as usual.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Trial of High Dose Influenza Vaccine in Long Term Care Setting

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Residents of one of the participating LTC sites~* 65 years or older at the time of consent~* require assistance in two or more Instrumental Activities of Daily Living and/or one or more Activities of Daily Living as identified by facility staff~Exclusion Criteria:~* Age less than 65 years~* Life expectancy less than 6 months~* History of allergic reaction to influenza vaccine, its components, or eggs~* History of severe allergic reaction to latex~* History of Guillian-Barre Syndrome~* Actively undergoing chemotherapy~* Actively undergoing radiation therapy~* Use of prednisone (or other steroid) at prednisone-equivalent dosages of 10mg or higher within the past 14 days~* Serious current immunosuppression or immunosuppression expected in the next 6 weeks~* Any condition that, in the opinion of the investigator,might interfere with the evaluation of study objectives

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- High Dose Inactivated Influenza Vaccine (Type: ACTIVE_COMPARATOR): For HDIV,0.5 ml of high dose inactivated influenza vaccine consisting of a total of 180mcg (60 mcg each strain) of influenza virus hemagglutinin
- Standard Dose Inactivated Influenza Vaccine (Type: ACTIVE_COMPARATOR): For SDIV, 0.5 ml of standard dose inactivated influenza vaccine consisting of a total of 45 mcg (15 mcg of each strain) of influenza virus hemagglutinin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Protective Effect of EPA on Cardiovascular Events

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Eligible participants had a total cholesterol level of ≧250mg/dL(6.5m mol/L) at baseline.~* Hyperlipidemic patients with serum total cholesterol of 250mg/dL or more. (Measurement of serum total cholesterol)~* Serum total cholesterol should be measured twice at interval of 2-4weeks. A single measurement is acceptable if the cholesterol is measured by blood collection at fasting under strict compliance with dietary advice after withdrawal of the antihyperlipemic drug.~* (Wash Out) The wash out period of 4weeks (8 weeks for probucol) is necessary in patients under treatment with antihyperlipemic drug. However, if treatment with the antihyperlipemic drug was started within 6 months of the initiation of the study, the patient can participate in the study without the washout period.~Exclusion Criteria:~* Acute myocardial infarction occurring within last 6 months~* Unstable angina pectoris~* A history or complication of serious heart disease(severe arrhythmia, heart failure, cardiac myopathy, valvular disease, congenital disease, etc.)~* Receiving cardiovascular reconstruction within last 6 months~* Cerebrovascular disorders occurring within last 6 months~* Complication of serious hepatic disease or renal disease~* Malignant tumor~* Uncontrollable diabetes~* Hyperlipidemia arising from the following disease: Nephrotic syndrome, hypothyroidism, Cushing's syndrome, secondary hyperlipidemia due to other disease~* Hyperlipidemia due to some drugs such as steroid hormone~* Hemorrhage(hemophilia, capillary fragility, gastrointestinal ulcer, urinary tract hemorrhage, hemoptysis, vitreous hemorrhage, etc.)~* Hemorrhagic diathesis~* Hypersensitivity to the study drug formulation~* Patients intending to undergo surgery~* Patients judged to be inappropriate by the physician in charge

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Men With Hormone-refractory Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men \>/= 18 years of age with histologically confirmed prostate cancer~* Radiographic evidence of at least one bone metastasis~* Failure of at least one hormonal therapy as evidenced by a rising PSA~* Serum testosterone level of \<50 ng/dL~* ECOG PS 0, 1, or 2~* Adequate organ function~Exclusion Criteria:~* Current or prior IV bisphosphonate administration~* Current or prior oral bisphosphonates for bone mets~* Life expectancy of less than 6 months

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- zoledronic acid (Type: ACTIVE_COMPARATOR): None
- denosumab (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PALISADE Follow-on Study (ARC004)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Completion of the ARC003 study~* Written informed consent and/or assent from subjects/guardians as appropriate~* Use of effective birth control by sexually active female subjects of child-bearing potential~Key Exclusion Criteria:~* Early discontinuation from the ARC003 study~* Meets any longitudinally applicable ARC003 study exclusion criteria~* (Group 2 only) Failure to tolerate ≥ 443 mg cumulative of peanut protein with no or mild symptoms in the ARC003 study Exit DBPCFC~* Any other condition that, in the opinion of the Investigator, precludes participation for reasons of safety

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 (Placebo Crossovers) (Type: OTHER): Subjects who complete the placebo arm of ARC003 and consent to enroll in ARC004 (Group-1) will cross over to active treatment with AR101 using the same dosing regimen used in ARC003 in open-label fashion. Group 1 subjects may also be assigned to cohorts which test the gradual lengthening of dosing intervals. Following the completion of their longest tested dosing interval, Group 1 subjects will undergo an exit double-blinded placebo-controlled food challenge (DBPCFC).
- Group 2 (Active Rollovers) (Type: OTHER): Subjects who successfully complete the active arm of ARC003 and consent to enroll in ARC004 (Group-2) will consecutively enter treatment with AR101 in one of three cohorts which will test alternate dosing intervals. There will be a DBPCFC at the completion of the subject's longest tested dosing interval.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Does a Transabdominal Plane Block Decrease Patient Pain After Ventral Hernia Repair?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age 18 and older~* elective laparoscopic ventral (ventral, umbilical, incisional) hernia repair at Mount Sinai Hospital~Exclusion Criteria:~* age younger than 18~* allergic reaction to bupivacaine~* allergic reaction to opioids~* opioid substance abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Transabdominal Plane Block (Type: EXPERIMENTAL): Receiving Transabdominal Plane Block with 0.25% bupivacaine
- Non Transabdominal Plane Block (Type: PLACEBO_COMPARATOR): Receiving placebo saline injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Specified Drug Use Results Survey of Ipragliflozin Treatment in type2 Diabetes Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with type 2 diabetes who first use Suglat Tablets during the period from July 17, 2014 to July 16, 2015~Exclusion Criteria:~* off-label use patients

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Suglat group (Type: None): Tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Estriol and Trimegestone Dose-response Trial With Single Dose Application of Vaginal Rings

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Under treatment with a commercially available combined oral contraceptive containing 30 µg ethinylestradiol (EE) and 150 µg levonorgestrel (LVN) for the last 3 months prior to enrolment~* Body-mass index (BMI): ≥ 18.5 kg/m² and ≤ 30.0 kg/m²~* Good state of health~* Non-smoker, ex-smoker for at least 3 months~* Regular menstrual cycle with a length between 21 and 35 days~* Written informed consent, after having been informed about benefits and potential risks of the clinical trial~Exclusion Criteria:~* Existing diseases or pathological findings, which might interfere with the safety or tolerability, and/or pharmacokinetics of the IMPs~* Subjects with severe allergies or multiple drug allergies~* Positive anti human immunodeficiency virus (anti-HIV) test, hepatitis B surface antigen (HBs-AG) test or anti hepatitis C virus (anti-HCV) test~* Presence or history of venous or arterial thrombosis, cerebrovascular accident, or increased risk of thrombosis~* Diabetes mellitus~* Unclarified vaginal bleeding or frequent infections of the urogenital tract~* Severe or chronic constipation~* Presence or history of migraine~* Drug or alcohol dependence~* Blood donation or other blood loss of more than 400 ml within the last 3 months~* Participation in a clinical trial during the last 6 months~* Pregnant or lactating women~* Subjects who do not agree to apply a barrier method for contraception

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- Test 1 vaginal ring (Type: EXPERIMENTAL): Single intravaginal application of 1 vaginal ring of Estriol 0.400 mg/day and Trimegestone 0.06 mg/day (Test 1) over 21 days
- Test 2 vaginal ring (Type: EXPERIMENTAL): Single intravaginal application of 1 vaginal ring of Estriol 0.300 mg/day and Trimegestone 0.12 mg/day (Test 2) over 21 days
- Test 3 vaginal ring (Type: EXPERIMENTAL): Single intravaginal application of 1 vaginal ring of Estriol 0.200 mg/day and Trimegestone 0.18 mg/day (Test 3) over 21 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Meditation and Kundalini Yoga for Heightened Anxiety Related to COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Heightened anxiety triggered or exacerbated by COVID-19~2. Anxiety it least mild-moderate in severity~3. English speaking and living in the United States~4. Access to a smart phone, tablet, or computer with internet~5. Able to read and understand English~Exclusion Criteria:~1. Individuals with severe depression or substance abuse~2. Individuals with a current or past history of psychosis, bipolar disorder, or PTSD.~3. Individuals with physical disability that might make study participation difficult.~4. Individuals with an unstable medical illness or a history of cardiac disease~5. Individuals with a current daily practice of meditation or Kundalini yoga~6. Individuals with confirmed or suspected COVID-19~7. Individuals who are currently pregnant or anticipate being pregnant during study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Anxiety Reduction Training (A.R.T.) (Type: ACTIVE_COMPARATOR): Participants will received biweekly on-line lessons that provide education and strategies to reduce stress and disturbing thoughts and improve healthy coping and sleep. .
- ART and Kundalini Yoga (Type: EXPERIMENTAL): This combines ART with a daily 30 minute practice of Kundalini Yoga (stretching, guided breathing, and meditation). Accessible by smart phone, tablet or computer.
- ART and Meditation (Type: EXPERIMENTAL): This combines ART with a daily 15 minute meditation with stress reduction techniques and guided breathing.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Boiled Peanut Oral Immunotherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 1-16 years~* History of immediate hypersensitivity reaction to peanut~* Evidence of IgE mediated peanut hypersensitivity within a 12 month period of study enrollment~* SPT with wheal/flare of at least 3 x 6 mm and/or Peanut specific IgE \>0.35 kU/L~Exclusion Criteria:~* History of life threatening peanut anaphylaxis~* Asthma requiring more than medium dose ICS~* Prior participation in oral immunotherapy, sublingual immunotherapy or epicutaneous immunotherapy~* Oat allergy~* Cardiovascular Disease~* Use of beta-blockers (oral), angiotensin converting enzyme inhibitors, angiotensin receptor blockers, or calcium channel blockers~* Use of steroid medications in the following manners:~* Daily oral steroid dosing for greater than 1 month during the past year~* Burst or steroid course in the past 3 month before inclusion~* Greater than 2 bursts oral steroid courses in the past year of at least 1 week duration~* Pregnancy or lactation~* Eosinophilic Gastrointestinal Disease~* History of food protein-induced enterocolitis~* History of developmental delay or speech delay that precludes age- appropriate communication, in the opinion of the investigator

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- Boiled Peanut Powder (Type: EXPERIMENTAL): Boiled Peanut Powder

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Adalimumab in Adult Chinese Rheumatoid Arthritis Subjects Treated With Methotrexate

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Met ACR criteria for diagnosis of active rheumatoid arthritis (RA) and have had at both the Screening visit and Week 0 visit at least four swollen joints (out of 66 assessed) and at least six tender joints(out of 68 assessed)~* Subjects must have failed prior treatment with one or more disease-modifying antirheumatic drugs (DMARDs)~* DMARDs (other than methotrexate \[MTX\]) must have been discontinued for \>= 28 days or at least 5 half-lives, whichever is greater, before the Week 0 visit~* Traditional Chinese Medicines must have been discontinued for \>= 28 days before the Week 0 visit~* Subjects must have received at least three months of treatment with MTX (minimum 7.5 mg/week) and remained on a stable dose of MTX for \>= 28 days prior to the Screening visit~* Glucocorticoids equivalent to \<= 10 mg of prednisone and prednisone equivalent must have remained unchanged for at least 28 days prior to the Week 0 visit~* Must have been able and willing to give written informed consent and to comply with the requirements of this study protocol~Exclusion Criteria:~* A history of, or current, acute inflammatory joint disease of different origin (e.g., mixed connective tissue disease, seronegative spondyloarthropathy, psoriatic arthritis, Reiter's syndrome, systemic lupus erythematosus, fibromyalgia or any arthritide with onset prior to age 16 years~* Wheelchair-bound or bedridden~* Joint surgery involving joints to be assessed within this study, within two months prior to the Screening visit~* Intra-articular, intramuscular or intravenous administration of corticosteroids within 28 days prior to the Screening visit~* Prior treatment with any TNF antagonist, including adalimumab~* Subject considered by the investigator, for any reason, to be an unsuitable candidate~* Female subject who is pregnant or breast-feeding or considering becoming pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo administered subcutaneously every other week
- Adalimumab 80 mg (Type: EXPERIMENTAL): Adalimumab 80 mg administered subcutaneously every other week
- Adalimumab 40 mg (Type: EXPERIMENTAL): Adalimumab 40 mg administered subcutaneously every other week

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of VESIcare® In Overactive Bladder (OAB) Subjects to Evaluate Symptom Bother and Health Related Quality of Life

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ambulatory male or female subject ≥ 18 years of age and able to use the toilet without difficulty~* History of OAB symptoms for ≥ 3 months~* An average of ≥ 8 micturitions per 24 hours and ≥ 1 urgency episode (with or without incontinence) per 24 hours as documented in a 3-day micturition diary~* Subjects are bothered by symptoms as reflected by PPBC ≥3~Exclusion Criteria:~* Evidence of chronic urologic inflammation such as interstitial cystitis and bladder stones; uncontrolled narrow angle glaucoma; urinary or gastric retention~* Recurrent urinary tract infection (UTI) of \> 3 episodes within the last 3 months or evidence of a urinary tract infection at Baseline Visit (Visit 2)~* Significant stress incontinence or mixed stress/urge incontinence where stress is the predominant factor as determined by the investigator~* History of renal or hepatic impairment(2 x Upper Limit of Normal(ULN) values in parameters and considered clinically significant by the investigator~* History of diagnosed gastrointestinal obstruction disease~* Subject has a known diagnosis or history of carcinoma (including prostate cancer) except non metastatic basal or squamous cell carcinoma of the skin that has been successfully treated or previous pelvis radiation within the past five years~* Known or suspected hypersensitivity to solifenacin succinate, any components, or other anticholinergics

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: ACTIVE_COMPARATOR): Matching placebo tablet taken once daily
- Solifenacin Succinate (Type: EXPERIMENTAL): 5mg or 10mg tablet taken once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete